nach oben

Drugs in R&D

Erschienen in:

01.01.2003 | Adis R&D Profile

Cinacalcet

Amg 073, Calcimimetics — Amgen/NPS Pharmaceuticals

Erschienen in: Drugs in R&D | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Excerpt

Cinacalcet [AMG 073] is an orally active, second generation calcimimetic compound licensed by NPS Pharmaceuticals to Amgen in the US for the potential treatment of hyperparathyroidism (HPT).¹ Cinacalcet modulates (increases the sensitivity of) calcium receptors on the surface of parathyroid cells thereby inhibiting the oversecretion of parathyroid hormone that characterises HPT. …

This profile has been selected from R&D Insight−, a pharmaceutical intelligence database produced by Adis International Ltd.

Wang B, Osborn K, Blaisdell P, Brenner R, Turner S, et al. Pharmacokinetics of calcimimetic AMG 073 in secondary hyperparathyroidism. Clinical Pharmacology and Therapeutics 69: P91, Feb 2001

Peacock M, Bilezekian JP, Turner SA, Guo MD, McCary LC, et al. Long-term treatment with the calcimimetic AMG 073 in patients with primary hyperparathyroidism. 84th Annual Meeting of the Endocrine Society: 92–93, 19 Jun 2002. Indiana University School of Medicine, Indianapolis, Indiana, USA; Amgen Inc., Thousand Oaks, California, USA

Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology. 13: 1017–1024, Apr 2002. Goodman WG, Univ Calif Los Angeles, Med Ctr, Div Nephrol, Sch Med, Dept Med, 7–155 Factor Bldg, 10833 Le Conte Ave, Los Angeles, CA 90095 USAPubMed

Amgen. First-In-Class Oral Calcimimetic Shown To Reduce Parathyroid Hormone Levels In Chronic Kidney Disease. Media Release: 3 Nov 2002. Available from URL: http://www.amgen.com

NPS Pharmaceuticals Inc. Positive phase II data on calcimimetics reported at medical meetings (NPS Pharmaceuticals). Media Release: [2 pages], 18 Oct 2001. Available from URL: http://www.npsp.com

Titel: Cinacalcet
Amg 073, Calcimimetics — Amgen/NPS Pharmaceuticals
Publikationsdatum: 01.01.2003
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 1/2003
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200304010-00006

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Cinacalcet

Amg 073, Calcimimetics — Amgen/NPS Pharmaceuticals

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2003

Morphine/Dextromethorphan — Endo

Ferumoxtran-10

Trabectedin

Profile Summary

MT 100

Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease